Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6058-6060
10.1182/blood-2022-163795